Illumina, Inc.
Illumina Announces New CFO and Strategic Officer Appointments
Summary
Illumina, Inc. announced on April 9, 2024, that Joydeep Goswami is leaving the company and will transition to an advisory role until June 30, 2024. Ankur Dhingra has been appointed as the new Chief Financial Officer, effective April 15, 2024. Additionally, Jakob Wedel has been named Chief Strategy and Corporate Development Officer. The company also reaffirmed its financial guidance for Q1 2024 and the full year 2024. These announcements were made in a press release and are incorporated by reference in the 8-K filing.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement